HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chromosomal abnormality rate in human pre-embryos derived from in vitro fertilization cycles cultured in the presence of Follicular-Fluid Meiosis Activating Sterol (FF-MAS).

AbstractBACKGROUND:
The objective of the study was to investigate the effect of Follicular-Fluid Meiosis Activating Sterol (FF-MAS) when added to the culture media on the incidence of chromosomal abnormalities and pre-embryo development in human pre-embryos.
METHODS:
243 women undergoing IVF/ICSI treatment donated 353 oocytes in a multicentre, prospective, randomized, double blind, four-arm, controlled trial performed at Danish and Swedish public and private IVF centers. Metaphase II oocytes were randomly assigned to: FF-MAS 5 microM, FF-MAS 20 microM, ethanol 0.2% (vehicle control) or water for injection (inert control). The exposure regimen of FF-MAS to the human oocytes was 4 h prior to fertilization by ICSI and 20 h exposure post ICSI. The primary endpoint was the incidence of numerical chromosomal abnormalities. Secondary endpoints were cleavage rate and pre-embryo quality.
RESULT:
On the pre-embryo level, no significant differences in chromosomal abnormality rate were observed among the four groups. However, the percentage of uniformly normal pre-embryos was significantly lower in the pooled FF-MAS group (5 microM: 12% and 20 microM: 17%) than in the pooled control group (inert control 32% and vehicle control 42%). A high level of mosaicism (41-60%) was found in all groups. At the blastomere level, the percentage of blastomeres categorized as normal was significantly lower in the FF-MAS 5 microM group (41%) and the FF-MAS 20 microM (29%) group versus the inert (52%) and the vehicle (61%) groups. Significantly reduced cleavage and good quality pre-embryo rates were found in both FF-MAS groups.
CONCLUSION:
FF-MAS increased the rate of aneuploidy and had detrimental effects on cleavage and pre-embryo development, when exposed both before and after fertilization.
AuthorsChristina Bergh, Anne Loft, Kersti Lundin, Sören Ziebe, Lars Nilsson, Matts Wikland, Christian Gröndahl, J-C Arce, CEMAS II Study Group
JournalHuman reproduction (Oxford, England) (Hum Reprod) Vol. 19 Issue 9 Pg. 2109-17 (Sep 2004) ISSN: 0268-1161 [Print] England
PMID15243006 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Cholestenes
  • 4,4-dimethylcholesta-8,14,24-trienol
Topics
  • Adult
  • Blastocyst (cytology, physiology, ultrastructure)
  • Blastomeres (cytology, physiology)
  • Cells, Cultured
  • Cholestenes (administration & dosage, analysis, pharmacology)
  • Chromosome Aberrations (statistics & numerical data)
  • Cleavage Stage, Ovum (drug effects)
  • Cytogenetic Analysis
  • Cytoplasm (ultrastructure)
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Embryonic Development
  • Female
  • Fertilization
  • Fertilization in Vitro
  • Follicular Fluid (chemistry)
  • Humans
  • Metaphase
  • Mosaicism
  • Oocytes (drug effects)
  • Osmolar Concentration

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: